ArticleBlood2011
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.The Journal of clinical investigation · 2015Trial
- High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.Blood advances · 2026Article
- The role of TCF-1+CD8+ exhausted progenitors and TCF-1 in graft-versus-host responses.JCI insight · 2025Article
- Review
- Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells.Immunity · 2023Article
- Separation of GVL from GVHD -location, location, location.Frontiers in immunology · 2023Review
- Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?Frontiers in immunology · 2022Review
- Selective depletion of naïve T cells by targeting CD45RA.Frontiers in oncology · 2022Review
- Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.Frontiers in immunology · 2022Review
- Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.Frontiers in pediatrics · 2021Review
- T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.Frontiers in immunology · 2021Review
- The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.Frontiers in immunology · 2021Review
- T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect.Nature communications · 2020Article
- T cell optimization for graft-versus-leukemia responses.JCI insight · 2020Review
- Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Review
- Minor Histocompatibility Antigen-Specific T Cells.Frontiers in pediatrics · 2020Review
- Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.Frontiers in immunology · 2020Review
- T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.Frontiers in immunology · 2020Review
- H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.Frontiers in immunology · 2020Review
- Identifying a Minor Histocompatibility Antigen in Mauritian Cynomolgus Macaques Encoded byFrontiers in immunology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Donor T cells contribute to the success of allogeneic hematopoietic stem cell transplantation (alloSCT). Alloreactive donor T cells attack leukemia cells, mediating the GVL effect. Donor T cells, including the memory T cells (T(M)) that are generated after infection, also promote immune reconstitution. Nonetheless, leukemia relapse and infection are major sources of treatment failure. Efforts to augment GVL and immune reconstitution have been limited by GVHD, the attack by donor T cells on host tissues. One approach to augmenting GVL has been to infuse ex vivo-generated T cells with defined specificities; however, this requires expertise that is not widely available. In the present study, we tested an alternative approach, adoptive immunotherapy with CD8+ T(M) from donors vaccinated against a single minor histocompatibility antigen (miHA) expressed by leukemia cells. Vaccination against the miHA H60 greatly augmented T(M)-mediated GVL against mouse chronic-phase (CP-CML) and blast crisis chronic myeloid leukemia (BC-CML). T(M)-mediated GVL was antigen specific and was optimal when H60 expression was hematopoietically restricted. Even when H60 was ubiquitous, donor H60 vaccination had a minimal impact on GVHD. T(M) from lymphocytic choriomeningitis virus (LCMV)-immune and H60-vaccinated donors augmented GVL and protected recipients from LCMV. These data establish a strategy for augmenting GVL and immune reconstitution without elaborate T-cell manipulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.